Clinical Trials

    Showing 1 - 3 of 3 pancreatic cancer

    A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evalu... Read more >

    Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

    Status: Enrolling

    Investigator: Nestor Esnaola

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvan... Read more >

    Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)

    Status: Enrolling

    Investigator: Kevin Tran

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options inc... Read more >